UB spinout POP Biotechnologies receives up to $9.7 million to advance rapid-response vaccine platform

UB spinout company POP Biotechnologies, co-founded by Jonathan Lovell, will receive nearly $10 million to advance a rapid-response vaccine platform. The Buffalo News also reported on the funding.